ArticleJournal of neuro-oncology2017
The ratio of HLA-DR and VNN2
Article in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Blood Biomarkers of Glioma in Response Assessment Including Pseudoprogression and Other Treatment Effects: A Systematic Review.Frontiers in oncology · 2020Pooled it
- Liquid Biopsy-Derived Tumor Biomarkers for Clinical Applications in Glioblastoma.Biomolecules · 2025Review
- Circulating biomarkers in high-grade gliomas: current insights and future perspectives.Journal of neuro-oncology · 2025Review
- New Insights into Monocyte-Derived Macrophages in Glioblastoma.Research (Washington, D.C.) · 2025Review
- Single cell RNA-seq reveals cellular and transcriptional heterogeneity in the splenic CD11bMolecular medicine (Cambridge, Mass.) · 2024Article
- Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.Journal of hematology & oncology · 2024Review
- Enrichment of a neutrophil-like monocyte transcriptional state in glioblastoma myeloid suppressor cells.Research square · 2023Article
- Review
- Assessment and prediction of glioblastoma therapy response: challenges and opportunities.Brain : a journal of neurology · 2023Article
- Healthy myeloid-derived suppressor cells express the surface ectoenzyme Vanin-2 (VNN2).Molecular immunology · 2022Article
- Integrated analysis of Helicobacter pylori-related prognostic gene modification patterns in the tumour microenvironment of gastric cancer.Frontiers in surgery · 2022Article
- Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: does pathology predict outcomes?Journal of neuro-oncology · 2021Article
- Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients.Frontiers in immunology · 2021Article
- Article
- Article
- Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma.Disease markers · 2020Review
- Article
- Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology.Neuro-oncology · 2019Review
- The transcriptional profile of circulating myeloid derived suppressor cells correlates with tumor development and progression in mouse.Genes and immunity · 2019Article
- Cerebral Radiation Necrosis: Incidence, Pathogenesis, Diagnostic Challenges, and Future Opportunities.Current oncology reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Glioblastoma (GBM) is the most aggressive and lethal type of brain cancer with a median survival of less than two years even following aggressive treatment (Stupp et al., N Engl J Med 352:987-996, 2005). Among the many challenges in treating patients with this devastating disease is the ability to differentiate Magnetic Resonance Imaging (MRI) images that appear following radiation therapy, often termed "radiation necrosis" from true GBM recurrence. Radiation necrosis (RN) and GBM are very difficult to distinguish and currently only a brain biopsy can conclusively differentiate these pathologies. In the present study, we introduce a differential diagnostic approach using a newly identified Myeloid-Derived Suppressor Cell (MDSC) biomarker, vascular non-inflammatory molecule 2 (VNN2
Indexed as
Identifiers
28551851What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.